Paper Details

  1. Home
  2. Paper Details

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.

Author: BrunnerK, CooperM R, CornwellG G, CuttnerJ, GlowienkaL P, HauraniF I, HendersonE, KochwaS, KyleR A, McIntyreO R, PajakT F, RaflaS, SilverR T

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study of 361 patients with previously untreated multiple myeloma found that oral melphalan was superior to BCNU and CCNU in producing objective responses. Melphalan also resulted in longer survival in good-risk patients. The addition of vincristine and prednisone did not significantly improve response rates or survival.
Paper Details　
Original Abstract of the Article :
A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0.15 mg/kg/day for seven days, followed by 0.05 mg/kg/day after recovery from the nadir of the leukocytes), BCNU (150 mg/m2 intravenously every six weeks) or CCNU (100 mg/m2 orally...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/1097-0142(19821101)50:9<1669::aid-cncr2820500902>3.0.co;2-n

データ提供：米国国立医学図書館（NLM）

A Race Against Time: Exploring Treatments for Multiple Myeloma

This research delves into the [medical field: oncology] landscape, examining treatment options for multiple myeloma, a type of blood cancer. The study utilizes [research methodology: randomized controlled trial] to compare the effectiveness of different chemotherapy regimens in treating multiple myeloma. The authors analyzed data from 361 patients, comparing the outcomes of treatment with oral melphalan, BCNU, and CCNU, with and without the addition of vincristine and prednisone. The study provides valuable insights into the efficacy of different treatment approaches for multiple myeloma and highlights the importance of personalized therapy based on individual patient characteristics.

A Race Against Time: Finding the Right Path

This research underscores the importance of finding the right treatment approach for multiple myeloma, a race against time. The study reveals that oral melphalan is a superior option for producing objective responses compared to BCNU and CCNU, particularly for patients with a good prognosis. The findings highlight the need for personalized therapy, tailoring treatment strategies to the specific needs of each patient.

Navigating the Desert of Cancer Treatment

Navigating the desert of cancer treatment can be a challenging journey for both patients and healthcare providers. This research offers a valuable guide for clinicians seeking to optimize treatment strategies for multiple myeloma. The study highlights the importance of personalized therapy and underscores the need for ongoing research to develop more effective and targeted treatments. Remember, seeking expert medical advice and exploring available treatment options is crucial for managing cancer and maximizing the chances of a positive outcome.

Dr.Camel's Conclusion

This research offers valuable insights into the treatment of multiple myeloma, a challenging cancer that requires a tailored and personalized approach. The study highlights the importance of choosing the right chemotherapy regimen based on individual patient characteristics and the need for ongoing research to develop more effective treatments. Just as a camel navigates the vast and unforgiving desert, clinicians must carefully select the right path for each patient to ensure the best possible outcome in the fight against multiple myeloma.

Date :
  1. Date Completed 1982-12-03
  2. Date Revised 2019-06-20
Further Info :

Pubmed ID

7116299

DOI: Digital Object Identifier

10.1002/1097-0142(19821101)50:9<1669::aid-cncr2820500902>3.0.co;2-n

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.